Disc Medicine (symbol: IRON) is a clinical-stage precision medicine company focused on the research and development of therapeutic compounds. Based on the description of its operations, the company's drug candidates are currently undergoing clinical trials and have not yet reached the stage of commercialization or market sales.

Therefore, Disc Medicine does not have major commercial customers in the traditional sense, as it does not sell products or services directly to other companies or individuals at this stage of development. Companies at this stage typically focus on advancing their pipeline through clinical development and may generate funding through collaborations, partnerships, licensing agreements, grants, or investments, rather than through direct product sales.

John Quisel, Chief Executive Officer

John Quisel was appointed CEO of Disc Medicine in February 2020. Prior to joining Disc Medicine, he spent over thirteen years at Acceleron Pharma, where he served as Chief Business Officer and other roles including General Counsel and Senior Vice President of Corporate Development. He was instrumental in building Acceleron from a privately-held startup into a public biotechnology company. Quisel also led the in-licensing of sotatercept and helped negotiate the collaboration agreement for luspatercept. Before Acceleron, he worked at the law firms of Ropes & Gray and Foley Hoag.

Jean Franchi, Chief Financial Officer

Jean Franchi became Disc Medicine's Chief Financial Officer on February 7, 2024. She brings over 30 years of finance leadership experience from both public and private biotechnology companies. Her previous roles include serving as Chief Financial Officer for Replimune, where she helped raise over $750 million. She also held CFO positions at Merrimack Pharmaceuticals, Dimension Therapeutics (which was acquired by Ultragenyx), and Good Start Genetics. Earlier in her career, Ms. Franchi spent 16 years at Genzyme, including eight years as Senior Vice President of Finance, and was involved in the company's $20.1 billion sale to Sanofi.

Jonathan Yu, Chief Operating Officer

Jonathan Yu was promoted to Chief Operating Officer of Disc Medicine on February 7, 2024. He previously served as the Chief Business Officer at Disc. He holds an M.B.A.

William Savage, Chief Medical Officer

Dr. William Savage serves as the Chief Medical Officer of Disc Medicine. He holds an M.D. and a Ph.D.

Pamela Stephenson, Chief Commercial Officer

Pamela Stephenson is the Chief Commercial Officer at Disc Medicine. She holds an M.P.H.

The key risks for Disc Medicine (symbol: IRON) are primarily associated with its status as a clinical-stage biopharmaceutical company focused on developing novel treatments for hematologic diseases. Disc Medicine, Inc. is the result of a merger with Gemini Therapeutics, Inc. in an all-stock transaction in August 2022, with the combined entity operating under the Disc Medicine name and ticker IRON.

1. Uncertainty of Clinical Trial Success and Regulatory Approval: As a clinical-stage company, Disc Medicine's business heavily relies on the successful outcome of its clinical trials and subsequent regulatory approvals for its pipeline candidates, including bitopertin, DISC-0974, and DISC-3405. A recent example of this risk materializing is the Complete Response Letter (CRL) received from the FDA in February 2026 for its lead candidate, bitopertin, for erythropoietic protoporphyria (EPP), which led to a significant decline in stock price.

2. Reliance on External Financing and Potential for Shareholder Dilution: Disc Medicine is a pre-revenue company that experiences substantial operating losses and negative free cash flow due to the high costs associated with drug development. The company's continued operation and advancement of its pipeline are dependent on its ability to secure additional external financing, which carries the inherent risk of diluting existing shareholders' equity. The widened net loss in 2025 and a recent common stock shelf registration underscore ongoing funding needs and capital structure priorities.

3. High Stock Volatility: The biotechnology sector is known for its volatility, and Disc Medicine is no exception. The company's stock exhibits a high beta, suggesting greater price fluctuations compared to the broader market. This volatility is often exacerbated by news related to clinical trial results, regulatory decisions, and financing activities, making it a high-risk investment.

Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company's main product candidates, bitopertin, DISC-0974, and DISC-3405, target several addressable markets.

Bitopertin

Bitopertin is being developed for Erythropoietic Protoporphyria (EPP) and X-linked protoporphyria (XLP). The global addressable market for erythropoietic porphyria therapeutics, which includes both EPP and XLP, was valued at approximately $850.0 million in 2025 and is projected to grow to about $2.74 billion by 2034. North America represented a significant portion of this market, holding a 42.3% revenue share in 2025.

DISC-0974

DISC-0974 is in development for several indications, including anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD).

• For anemia of myelofibrosis (MF), the addressable market opportunity is estimated at $5.5 billion in the U.S. This estimate is based on approximately 22,000 U.S. patients.
• For anemia of chronic kidney disease (CKD), the market across the seven major markets (7MM: U.S., France, Germany, Italy, Spain, UK, and Japan) is projected to grow from $4.4 billion in 2024 to $5.3 billion in 2034. The U.S. alone accounted for an estimated $2.1 billion in drug sales in 2024 for CKD anemia and is expected to reach $2.7 billion in 2034.

DISC-3405

DISC-3405 targets Polycythemia Vera (PV) and Sickle Cell Disease (SCD).

• The addressable market for Polycythemia Vera (PV) in the seven major markets (7MM: U.S., EU4, UK, Japan) was approximately USD 1.9 billion in 2024. This market is projected to grow to USD 5.257 billion by 2034. The U.S. market specifically for Polycythemia Vera was estimated at approximately USD 1.44 billion in 2024.
• The global addressable market size for Sickle Cell Disease (SCD) treatment was valued at USD 4.03 billion in 2024 and is expected to reach USD 13.06 billion by 2033. North America held approximately 38.7% of this global market in 2024. Another estimate places the global market at USD 3.94 billion in 2025, growing to USD 20.47 billion by 2034.

1. Commercialization of Bitopertin for Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP): Disc Medicine's lead candidate, bitopertin, is being developed for EPP and XLP. Although the company received a Complete Response Letter (CRL) from the FDA for bitopertin in EPP, the FDA indicated that data from the ongoing Phase 3 APOLLO trial could support traditional approval. Topline data from the APOLLO study are anticipated in the fourth quarter of 2026, with a potential FDA decision by mid-2027, which would mark Disc Medicine's transition to a commercial-stage company. The market for EPP/XLP represents a significant opportunity due to unmet medical needs and strong patient demand for an effective treatment.
2. Advancement and Potential Approval of DISC-0974 for Anemia of Myelofibrosis (MF): DISC-0974, an anti-hemojuvelin antibody, has shown positive Phase 2 data in patients with myelofibrosis and anemia, demonstrating strong efficacy in improving hemoglobin levels and reducing transfusion dependence. Updated data from the Phase 2 study in myelofibrosis is expected in the second half of 2026. The myelofibrosis anemia market is substantial, estimated at approximately $5.5 billion in the U.S., with DISC-0974 having the potential to address a critical treatment gap, especially for patients on JAK inhibitor therapy.
3. Expansion of DISC-0974 into New Indications: Beyond myelofibrosis, Disc Medicine is expanding the development of DISC-0974 to address anemia in other conditions. The company plans to initiate a Phase 2 study for DISC-0974 in patients with anemia and inflammatory bowel disease (IBD). DISC-0974 is also being developed for anemia of chronic kidney disease (CKD). Successful clinical development and subsequent approval in these additional indications would significantly broaden the addressable patient population and market potential for DISC-0974, driving further revenue growth.
4. Progression of DISC-3405 in Polycythemia Vera (PV) and Sickle Cell Disease (SCD): Initial data from ongoing Phase 2 studies of DISC-3405 in polycythemia vera and Phase 1b studies in sickle cell disease are anticipated in the second half of 2026. Positive clinical readouts and subsequent advancement of DISC-3405 through later-stage development could unlock additional significant market opportunities within the hematology space, contributing to Disc Medicine's long-term revenue growth.

Share Issuance

• Disc Medicine completed equity offerings in January and October 2025, resulting in net proceeds of $454.4 million.
• In October 2025, Disc Medicine executed a $250 million upsized public offering, with $225 million in gross proceeds allocated to the company.
• The company raised $178 million in gross proceeds through an underwritten offering of common stock in June 2024.

Inbound Investments

• Disc Medicine secured a $90 million Series B financing in September 2021, led by OrbiMed and including new and existing investors.
• The company completed a $200 million non-dilutive debt financing in November 2024.
• Great Point Partners acquired a new position in Disc Medicine in Q4 2025, representing an estimated $19.85 million investment.

Capital Expenditures

• Capital expenditures were $0.93 million in 2025 and $0.51 million in 2024.
• In Q4 2025, Disc Medicine invested $20,000 in capital expenditures.
• These expenditures are primarily focused on funding long-term assets and infrastructure.